BRAF and acral lentiginous melanoma: We previously investigated our acral melanoma patient cohort and found that the results of immunohistochemistry (IHC) using VE1 antibody, which detects mutated BRAF V600E protein, were highly consistent with the results of an approved commercially available test, the Cobas BRAF V600E Mutation Test (Roche Diagnostics, Mannheim, Germany), and that there was intertumor and intratumor BRAF V600E heterogeneity [16].